Staging of hepatocellular carcinoma

Primary Liver Cancer: Surveillance, Diagnosis and Treatment

Volumn , Issue , 2012, Pages 161-175

  Bunchorntavakul, Chalermrat ^a   Hoteit, Maarouf ^a   Reddy, K Rajender ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907524590     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-61779-863-4_8     Document Type: Chapter

References (92)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5-16.
2. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995;22(2):432-8.
3. Manno M, Camma C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004;127(3):756-63.
4. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J Am Med Assoc. 2006;295(1):65-73.
5. Survival and stage of liver and intrahepatic bile duct cancers. http://seer.cancer.gov/statfacts/ html/livibd.html#survival . Accessed 28 Feb 2011.
6. Yamamoto J, Iwatsuki S, Kosuge T, et al. Should hepatomas be treated with hepatic resection or transplantation? Cancer. 1999;86(7):1151-8.
7. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30(6):1434-40.
8. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30(1):61-74.
9. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.
10. Christensen E, Schlichting P, Fauerholdt L, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology. 1984;4(3):430-5.
11. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56(4):918-28.
12. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28(3):751-5.
13. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol. 1999;31(1):133-41.
14. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329-38.
15. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38(3):207-15.
16. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-43.
17. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29(4):502-10.
18. Vauthey JN, Klimstra D, Franceschi D, et al. Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Am J Surg. 1995;169(1):28-34. discussion 34-25.
19. Lauwers GY, Terris B, Balis UJ, et al. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol. 2002;26(1):25-34.
20. Ikai I, Yamaoka Y, Yamamoto Y, et al. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann Surg. 1998;227(3):433-9.
21. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20(6):1527-36.
22. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol. 1996;105(1):65-75.
23. Poon RT, Fan ST. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am. 2003;12(1):35-50. viii.
24. Wu CC, Cheng SB, Ho WM, Chen JT, Liu TJ, P'Eng FK. Liver resection for hepatocellular carcinoma in patients with cirrhosis. Br J Surg. 2005;92(3):348-55.
25. Varotti G, Ramacciato G, Ercolani G, et al. Comparison between thefifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. Eur J Surg Oncol. 2005;31(7):760-7.
26. Ramacciato G, Mercantini P, Cautero N, et al. Prognostic evaluation of the new American Joint Committee on Cancer/International Union Against Cancer staging system for hepatocellular carcinoma: analysis of 112 cirrhotic patients resected for hepatocellular carcinoma. Ann Surg Oncol. 2005;12(4):289-97.
27. Lei HJ, Chau GY, Lui WY, et al. Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg. 2006;203(4):426-35.
28. Kee KM, Wang JH, Lee CM, et al. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 2007;120(12):2650-5.
29. Vauthey JN, Ribero D, Abdalla EK, et al. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg. 2007;204(5):1016-27. discussion 1027-1018.
30. Choi SB, Lee JG, Kim KS, et al. The prognosis and survival analysis according to seven staging systems of hepatocellular carcinoma following curative resection. Hepatogastroenterology. 2008;55(88):2140-5.
31. Vauthey JN, Lauwers GY. Prognostic factors after resection of hepatocellular carcinoma: are there landmarks in the wild forest? J Hepatol. 2003;38(2):237-9.
32. Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford). 2003;5(4):243-50.
33. Lu W, Dong J, Huang Z, Guo D, Liu Y, Shi S. Comparison of four current staging systems for Chinese patients with hepatocellular carcinoma undergoing curative resection: Okuda, CLIP, TNM and CUPI. J Gastroenterol Hepatol. 2008;23(12):1874-8.
34. Contreras CM, Vauthey JN. Staging systems: is there a surgical staging and a medical one? A surgeon's perspective. J Hepatobiliary Pancreat Sci. 2010;17(4):438-9.
35. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene LF, Trotti A. AJCC (American Joint Committee on Cancer) cancer staging manual. 7th ed. New York: Springer; 2010.
36. Japan lSGo. General Rules for the Clinical and Pathological Study of Primary Liver Cancer 2nd English [corresponds to the 2000 4th Japanese edition.] ed. Tokyo: Kanehara; 2003.
37. Ueno S, Tanabe G, Nuruki K, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res. 2002;24(4):395-403.
38. Makuuchi M, Belghiti J, Belli G, et al. IHPBA concordant classification of primary liver cancer: working group report. J Hepatobiliary Pancreat Surg. 2003;10(1):26-30.
39. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245(6):909-22.
40. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol. 2004;40(1):124-31.
41. Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with earlyintermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005;54(3):411-8.
42. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut. 2002;50(6):881-5.
43. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41(4):707-16.
44. Rabe C, Lenz M, Schmitz V, et al. An independent evaluation of modern prognostic scores in a central European cohort of 120 patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2003;15(12):1305-15.
45. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31(4):840-5.
46. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology. 2001;34(3):529-34.
47. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer. 2000;89(11):2266-73.
48. Siddique I, El-Naga HA, Memon A, Thalib L, Hasan F, Al-Nakib B. CLIP score as a prognostic indicator for hepatocellular carcinoma: experience with patients in the Middle East. Eur J Gastroenterol Hepatol. 2004;16(7):675-80.
49. Huitzil-Melendez FD, Capanu M, O'Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol. 2010;28(17):2889-95.
50. Marrero JA. Staging systems for hepatocellular carcinoma: should we all use the BCLC system? J Hepatol. 2006;44(4):630-2.
51. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7(1):35-41.
52. Toyoda H, Kumada T, Kiriyama S, et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol. 2005;100(8):1764-71.
53. Camma C, Di Marco V, Cabibbo G, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther. 2008;28(1):62-75.
54. Nanashima A, Morino S, Yamaguchi H, et al. Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma. Eur J Surg Oncol. 2003;29(9):735-42.
55. Nanashima A, Omagari K, Tobinaga S, et al. Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis. Eur J Surg Oncol. 2005;31(8):882-90.
56. Huo TI, Huang YH, Lin HC, et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol. 2006;101(5):975-82.
57. Kaseb AO, Hassan MM, Lin E, et al. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer . 2011;117(11):2478-88.
58. Tournoux-Facon C, Paoletti X, Barbare JC, et al. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol. 2011;54(1):108-14.
59. Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40(6):1396-405.
60. Chung H, Kudo M, Takahashi S, et al. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23(3):445-52.
61. Ikai I, Takayasu K, Omata M, et al. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41(9):884-92.
62. Nanashima A, Sumida Y, Abo T, et al. Modified Japan integrated staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy. J Gastroenterol. 2006;41(3):250-6.
63. Nanashima A, Sumida Y, Morino S, et al. The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol. 2004;30(7):765-70.
64. Huo TI, Lin HC, Huang YH, et al. The model for end-stage liver disease-based Japan Integrated scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer. 2006;107(1):141-8.
65. Kitai S, Kudo M, Minami Y, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan integrated staging score, the conventional Japan integrated staging score and the BALAD score. Oncology. 2008;75 Suppl 1:83-90.
66. Kitai S, Kudo M, Minami Y, et al. A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score. Intervirology. 2008;51 Suppl 1:86-94.
67. Yen YH, Changchien CS, Wang JH, et al. A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients. Dig Liver Dis. 2009;41(6):431-41.
68. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the cancer of the liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94(6):1760-9.
69. Leung TW, Mo F, Leow CK, et al. Multicenter validation of the Chinese University Prognostic Index (CUPI) of hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol. 2003;22:1040A.
70. Chan SL, Mo FK, Johnson PJ, et al. Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol. 2011;26(2):340-7.
71. Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut. 2005;54(3):419-25.
72. Yau T, Yao TJ, Chan P, Ng K, Fan ST, Poon RT. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials. Cancer. 2008;113(10):2742-51.
73. Omagari K, Honda S, Kadokawa Y, et al. Preliminary analysis of a newly proposed prognostic scoring system (SLiDe score) for hepatocellular carcinoma. J Gastroenterol Hepatol. 2004;19(7):805-11.
74. Nanashima A, Omagari K, Sumida Y, et al. Evaluation of new prognostic staging systems (SLiDe score) for hepatocellular carcinoma patients who underwent hepatectomy. Hepatogastroenterology. 2009;56(93):1137-40.
75. Toyoda H, Kumada T, Osaki Y, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol. 2006;4(12):1528-36.
76. Hsu CY, Huang YH, Hsia CY, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei integrated scoring system. J Hepatol. 2010;53(1):108-17.
77. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55.
78. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44(4):723-31.
79. Vitale A, Saracino E, Boccagni P, et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc. 2009;41(4):1260-3.
80. Guglielmi A, Ruzzenente A, Pachera S, et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103(3):597-604.
81. Beaugrand M, Sala M, Degos F, et al. Treatment of advanced hepatolcellular carcinoma by seocalcitol (a vit D analogue): an International randomized double-blind placebo-controlled study in 747 patients. J Hepatol. 2005;42 Suppl 2:17A.
82. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.
83. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
84. Takayama T, Makuuchi M, Hasegawa K. Single HCC smaller than 2 cm: surgery or ablation?: surgeon's perspective. J Hepatobiliary Pancreat Sci. 2010;17(4):422-4.
85. Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology. 1998;28(5):1241-6.
86. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35(3):519-24.
87. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429-42.
88. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734-9.
89. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164-71.
90. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394-403.
91. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2011 Hepatocellular Carcinoma. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp . Accessed 7 July 2011.
92. Meier V, Ramadori G. Clinical staging of hepatocellular carcinoma. Dig Dis. 2009;27(2):131-41.